Literature DB >> 12435845

Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine.

Geoffrey P Margison1, Mauro F Santibáñez Koref, Andrew C Povey.   

Abstract

Alkylating agents are a structurally diverse group of compounds that cause a wide range of biological effects, including cell death, mutation and cancer. DNA damaged by these agents contains widely different amounts of 12 alkylated purines/pyrimidines and two phosphotriester isomers. The biological effects appear to be mediated predominantly by attack at the O(6) position of guanine. DNA extracted from various normal human tissues contains detectable levels of O(6)-alkylguanine, the source of which has not been defined. Given that, following DNA replication, this lesion cannot only generate point mutations but can also initiate mismatch repair-mediated DNA recombination and cell death, it seems worthwhile to consider the possible contribution of these events and cell killing to the aetiology of human cancer. There is increasing evidence that point mutations are not the only mechanism involved in malignant transformation by alkylating agents. Some cancer chemotherapeutic agents exploit the cytotoxic effects of O(6)-alkylguanine and an understanding of the processing of this lesion has allowed strategies to be developed that should increase the effectiveness of such agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435845     DOI: 10.1093/mutage/17.6.483

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  62 in total

Review 1.  Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.

Authors:  Satya Narayan; Ritika Sharma
Journal:  Life Sci       Date:  2015-09-01       Impact factor: 5.037

2.  Exploring the roles of nucleobase desolvation and shape complementarity during the misreplication of O(6)-methylguanine.

Authors:  Delia Chavarria; Andrea Ramos-Serrano; Ichiro Hirao; Anthony J Berdis
Journal:  J Mol Biol       Date:  2011-07-23       Impact factor: 5.469

Review 3.  DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans.

Authors:  Byeong Hwa Yun; Jingshu Guo; Medjda Bellamri; Robert J Turesky
Journal:  Mass Spectrom Rev       Date:  2018-06-11       Impact factor: 10.946

Review 4.  Investigating the biochemical impact of DNA damage with structure-based probes: abasic sites, photodimers, alkylation adducts, and oxidative lesions.

Authors:  Heidi A Dahlmann; V G Vaidyanathan; Shana J Sturla
Journal:  Biochemistry       Date:  2009-10-13       Impact factor: 3.162

5.  Human colorectal mucosal O6-alkylguanine DNA-alkyltransferase activity and DNA-N7-methylguanine levels in colorectal adenoma cases and matched referents.

Authors:  N P Lees; K L Harrison; C N Hall; G P Margison; A C Povey
Journal:  Gut       Date:  2006-08-04       Impact factor: 23.059

6.  Time-matched analysis of DNA adduct formation and early gene expression as predictive tool for renal carcinogenesis in methylazoxymethanol acetate treated Eker rats.

Authors:  Valentina Klaus; Heinke Bastek; Katja Damme; Leonard B Collins; Roland Frötschl; Norbert Benda; Dominik Lutter; Heidrun Ellinger-Ziegelbauer; James A Swenberg; Daniel R Dietrich; Kerstin Stemmer
Journal:  Arch Toxicol       Date:  2017-03-27       Impact factor: 5.153

7.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

8.  Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

Authors:  L J Worrillow; A G Smith; K Scott; M Andersson; A J Ashcroft; G M Dores; B Glimelius; E Holowaty; G H Jackson; G L Jones; C F Lynch; G Morgan; E Pukkala; D Scott; H H Storm; P R Taylor; M Vyberg; E Willett; L B Travis; J M Allan
Journal:  J Med Genet       Date:  2007-10-24       Impact factor: 6.318

9.  Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Authors:  Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 10.  Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.

Authors:  Michael D Milsom; David A Williams
Journal:  DNA Repair (Amst)       Date:  2007-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.